Onyx multiple myeloma drug wins FDA fast-track status

UCSF nabs $20M gift from Ray and Dagmar Dolby for stem cell building

Douglas Rosenberg invests $3.5M toward Alzheimer's drug development at Buck Institute

BiPar breast cancer drug fails late-stage trial

Genentech's Rituxan wins FDA approval for advanced follicular lymphoma

Fluidigm prices IPO at $13.50 to $15 per share

Success with Genentech cancer drug Tarceva could end study early

Bionovo to raise $30M for R&D

UCSF to hire more San Francisco residents for hospital project

Portola Pharmaceuticals targets antidote to blood thinners

Plexxikon starts Phase I trial of rheumatoid arthritis drug

$26.3M Eye Institute at Stanford named for VC giant Brook Byers and wife

FDA warns Genentech about Boniva ad with Sally Field

The plane truth: Elan execs take flight in face of layoffs

Report: Elan cuts 130 jobs, mainly in South SF, as execs take private jet

FDA wants more info on Gilead-Tibotec HIV drug combo

Codexis signs deal with Japan's Dainippon Sumitomo Pharma

Abaxis inks $30 million supply deal with Becton Dickinson

Nektar nets $220M from stock sale

Portola Pharma names 1st head of R&D

AcelRx Pharmaceuticals prices $81 million IPO

UCSF harvesting Big Pharma deals

Genomic Health hiring 50-100, expanding to 3rd building

Genomic Health pedals way to growth

California stem cell agency CIRM taps Amgen exec for new R&D post

Transcept awakens bid for sleeping pill approval

Venture investing way up in '10, modest increase in biotech

Corcept Therapeutics to sell $39M in stock

View from personalized medicine confab

Gordon & Rees starts life sciences practice

Nektar Therapeutics to sell 19M shares

Plexxikon, Roche melanoma drug improves survival

Protagonist Therapeutics, Ironwood Pharma sign peptide drug deal

Amgen to sell Fremont campus to Boehringer Ingelheim

Nektar Therapeutics plans stock sale

Alexza shares plummet after FDA setback

Genentech fires back at FDA over Avastin breast cancer rejection

Calif. AG leads battle against Bayer, 'reverse payments'

UCSF opening $15.5 million high-tech learning center

We are the world: Bay Area remains center of biotech

Melanoma drug, companion diagnostic marry Plexxikon, Roche Molecular Diagnostics

Index Ventures opening Bay Area office

Medtronic completes $800M acquisition of Ardian

In autism's storm: 2 champions stand firm in light of discredited doctor

Biotechs fight proposed building code in South S.F.

FibroGen launches mid-stage IPF drug trial

SRI International lands $17.4M in NIH deals

Codexis inks enzyme supply deal with DSM Pharm

UCSF, Sanofi-Aventis ink research, intern deal

Dynavax fills late-stage hepatitis vaccine trial

NextWave Pharmaceuticals raises $45M

Fast facts from J.P Morgan's 1st day

Bayer, UCSF ink master deal, but few details

Sangamo gives layoffs the zinc finger

OncoMed starts early test of solid tumor cancer drug

What's up at the J.P. Morgan conference — so far

Exelixis cancer drug wins 'orphan' tag

InterMune to start new IPF drug trial

JP Morgan Healthcare Conference: And they're off …

IPierian wants closer ties to 'father' of induced pluripotent stem cells Yamanaka

23andMe snags another $9M in funding

Executive Profile: iPierian CEO Michael Venuti

StemCells lines up $10M stock financing

UCSF, University of Michigan, Cleveland Clinic artificial kidney could knock out dialysis

Avastin, Esbriet drug approvals: Go figure

Pfizer, Sutro cut peptide drug research deal

J.P. Morgan Healthcare Conference tops 2010 numbers

InterMune IPF drug strategy pays off

Affymax names new CEO, director

Genentech, Plexxikon ink sales deal

Denmark's Symphogen raises $130 million

FDA OKs expanded use of Genentech rheumatoid arthritis drug Actemra

Med device company PneumRx raises $33M

Boston Scientific buys remainder of Sadra Medical for $193M

Genentech licenses NY biotech's potential antibacterial compounds

Xoma gets flexibility in Servier deal, must deliver

Xoma snags up to $505M, including $35M upfront, for anti-inflammation/diabetes drug

New biotech conference crowds J.P. Morgan Week schedule

Biotech in '11: Life science firms dive into great unknown